Cresemba Европска Унија - Словеначки - EMA (European Medicines Agency)

cresemba

basilea pharmaceutica deutschland gmbh - isavukonazol - aspergiloza - cresemba je navedeno pri odraslih za zdravljenje:invazivne aspergillosismucormycosis pri bolnikih, za katere amphotericin b je inappropriateconsideration treba uradna smernice za ustrezno uporabo protiglivično agenti.

Lojuxta Европска Унија - Словеначки - EMA (European Medicines Agency)

lojuxta

amryt pharmaceuticals dac - lomitapide - hiperholesterolemija - sredstva za spreminjanje lipidov - lojuxta je navedena kot dodatek k dieti low‑fat in drugimi lipid‑lowering zdravili z ali brez citofereza nizko gostoto lipoproteinov (ldl), pri odraslih bolnikih s homozigotno družinsko hiperholesterolemijo (hofh). genetske potrditev hofh, je treba pridobiti, kadar je to mogoče. druge oblike primarne hyperlipoproteinaemia in sekundarne vzroke hypercholesterolaemia (e. nephrotic sindrom, hipotiroidizem) mora biti izključena.

Pifeltro Европска Унија - Словеначки - EMA (European Medicines Agency)

pifeltro

merck sharp & dohme b.v. - doravirine - okužbe z virusom hiv - antivirusi za sistemsko uporabo - pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with hiv 1 without past or present evidence of resistance to the nnrti class.

Brukinsa Европска Унија - Словеначки - EMA (European Medicines Agency)

brukinsa

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastična sredstva - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).